Abstract
1 min read<p>Expression and prognostic impact of tB-markers in TNBC. <b>A,</b> Unsupervised hierarchical clustering of the percentage of positive cells/sample in the discovery and validation cohorts of TNBC (<i>n</i> = 243). Color code denotes percentage of expression (blue, 0%; red, 100%). <b>B,</b> Scatter plots representing the percentage of tumor cells positive for SMA, TAGL, and TPM2 in two independent TNBC cohorts: the commercial TMA BR1301a (left) and the Cartagena cohort (right). Each dot represents one patient sample; horizontal lines indicate mean ± SEM. Statistical significance was determined using two-way ANOVA. ****, <i>P</i> < 0.0001. <b>C,</b> Heatmap showing the expression levels of the tB-markers across breast cancer samples. Expression values are row-normalized, ranging from low (blue) to high (red). The top annotations indicate relevant clinical and molecular characteristics of each sample, including histologic type, disease stage, intrinsic PAM50 subtype, and Lehmann classification (TNBC type_4). NA, not available; NOS, not otherwise specified. <b>D,</b> KM plot depicting RFS of patients with TNBC stratified by tB-marker expression. <b>E,</b> KM plot showing RFS in patients with TNBC treated exclusively with chemotherapy, based on tB-marker expression. <b>F,</b> KM plot illustrates OS of patients with TNBC based on tB-marker expression. In panels <b>D–F</b>, patient subgroups were defined through trichotomization, in which the lower quartile represents the “low expression” group (black), and the upper quartile represents the “high expression” group (red). Patients with intermediate expression levels were excluded to ensure a robust comparison between high and low expressers.</p>
Discussion(0)
No comments yet. Be the first to comment.